Welcome to our dedicated page for Alto Neuroscienc SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Alto Neuroscience director Manji Husseini received a stock option grant for 10,958 shares of common stock. The option has an exercise price of $24.63 per share and expires on May 11, 2036. The shares underlying the option vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. According to the disclosure, the option was issued under the non-employee director compensation policy and no cash consideration was paid for the grant. Following this award, Husseini holds options covering 10,958 shares directly.
Alto Neuroscience director Andrew Dreyfus received a grant of stock options covering 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. They vest on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting, as long as he continues in service through that date. According to the disclosure, he paid no cash consideration for this award, which was issued under the company’s Non-Employee Director Compensation Policy. Following this grant, he holds options for 10,958 shares directly.
Alto Neuroscience, Inc. director York Gwill received a grant of stock options covering 10,958 shares of common stock at an exercise price of $24.63 per share. The options were issued under the company’s Non-Employee Director Compensation Policy and required no cash payment by Gwill.
The options will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as Gwill continues to serve through that vesting date. After this grant, he holds options for 10,958 underlying shares directly.
Alto Neuroscience, Inc. reported results from its 2026 annual stockholder meeting. Of 31,945,516 common shares outstanding as of the record date, 26,762,809 shares, or about 83.77%, were represented, giving the company a strong quorum for voting.
Stockholders elected two Class II directors: Raymond Sanchez, M.D. received 23,133,161 votes for and 31,432 withheld, while Gwill York received 12,385,501 for and 10,779,092 withheld, with 3,598,216 broker non-votes for each. They ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 26,727,215 votes for. Stockholders did not approve an amendment and restatement of the 2024 Equity Incentive Plan related to treating pre-funded warrants like common shares for the plan’s evergreen share reserve, but did approve a similar amendment and restatement of the 2024 Employee Stock Purchase Plan.
Alto Neuroscience reported first quarter 2026 results, combining deeper investment in its precision psychiatry pipeline with a much stronger balance sheet. Cash, cash equivalents, and restricted cash rose to about $264.2 million as of March 31, 2026 from $177.0 million, reflecting net proceeds of roughly $115 million from a March 2026 PIPE financing.
The company advanced several key programs, including initiation of a potentially registrational Phase 2b trial of ALTO-207 in treatment-resistant depression, new supportive biomarker data for ALTO-101, and ongoing Phase 2b trials for ALTO-300 and ALTO-100 with enhanced patient-quality controls. Alto now expects topline data in 2027 across these mid‑ to late‑stage trials and guides its current cash runway to fund operations, including a potential NDA submission for ALTO-207, through 2029.
Operating expenses increased as R&D spending roughly doubled year over year, driving a larger net loss of $26.2 million (or $0.80 per share) for the quarter compared with $15.2 million (or $0.56 per share) a year earlier.
Alto Neuroscience filed a shelf registration to permit resale of up to 6,000,000 shares of common stock by recent private placement investors. The shares consist of 2,900,000 issued shares and 3,100,000 shares issuable upon exercise of pre-funded warrants. Alto received approximately $120.0 million gross proceeds from the Private Placement that closed on March 17, 2026. The company will not receive proceeds from resale by the selling stockholders, except for the nominal $0.0001 per-share exercise price if any Pre-Funded Warrants are exercised for cash. The registration covers resale mechanics, selling-stockholder tables (examples provided), and related indemnities and distribution methods. Alto common stock trades on the NYSE under ANRO (closing price shown April 9, 2026: $22.40).
Alto Neuroscience reported topline results from a Phase 2 proof-of-concept trial of ALTO-101 in cognitive impairment associated with schizophrenia. The drug did not achieve statistical significance on primary EEG or cognitive endpoints versus placebo, though directional EEG improvements were seen.
In a more cognitively impaired subgroup, ALTO-101 showed nominally significant benefits on the theta-ITC EEG measure, and several EEG signals improved between day 5 and day 10. ALTO-101 was well tolerated, with nausea and vomiting rates similar to placebo, suggesting its pharmacokinetic profile may address a key limitation of the PDE4 inhibitor class.
Alto has created a modified-release, once-daily oral formulation of ALTO-101 with improved pharmacokinetics and tolerability and plans to seek partners for this program rather than independently advancing ALTO-101 in CIAS. The company is prioritizing its lead program, ALTO-207 for treatment-resistant depression, with a Phase 2b trial in about 178 adults expected to start in the first half of 2026, supported by prior positive Phase 2a data. Management highlighted a cash position of $275 million and multiple advancing clinical programs.